Approval · Notice of Compliance 30543 · 2023
FINLIUS: Notice of Compliance 30543
Issued April 18, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30543
- Date
- April 18, 2023
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Labelling Only
- Reason
- Administrative - Additional product name
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FINLIUS | 02537303 | Marketed |
| FINLIUS | 02537257 | Marketed |
| FINLIUS I.V. | 02537311 | Marketed |
Medicinal ingredients
- USTEKINUMAB 45 MG per 0.5ML
- USTEKINUMAB 90 MG per 1ML
- USTEKINUMAB 5 MG per ML